Company: SCLXW
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047800
Chunk: 287

Company: Scilex Holding Co
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 287
---
 payable
    $
    4,602

    $
    —

    Conversion of Oramed Note into Tranche B Notes
    $
    25,000

    $
    —

    Conversion of Tranche B Notes into common stock
    $
    9,256

    $
    —

    Debt issuance costs included in accrued expenses
    $
    3,063

    $
    —

    Placement Agent Shares and October 2024 Placement Agent Warrants
    $
    3,792

    $
    —

    StockBlock Warrants issued in connection with the December 2024 RDO
    $
    1,265

    $
    —

    Conversion of Convertible Debentures into common stock
    $
    —

    $
    7,735

    Right-of-use assets obtained in exchange for operating lease liabilities with lease modification
    $
    —

    $
    2,523

    Oramed Note issuance at fair value
    $
    —

    $
    106,252

    Other non-cash consideration in connection with share repurchase
    $
    —

    $
    26,154

    Excise tax in connection with share repurchase included in accrued expenses
    $
    860

    $
    1,310

See accompanying notes to audited consolidated financial statements

 F-8

SCILEX HOLDING COMPANY 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. Nature of Operations and Basis of Presentation Organization and Principal Activities Scilex Holding Company (“Scilex” and together with its wholly owned subsidiaries, the “Company”) is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company was originally formed in 2019 and currently has five wholly owned subsidiaries, Scilex Inc. (“Legacy Scilex”), Scilex Pharmaceuticals Inc. (“Scilex Pharma”), Semnur Pharmaceuticals, Inc. (“Semnur”), SCLX DRE Holdings LLC and SCLX Stock Acquisition JV LLC. The business combination with Vickers (the “Business Combination”) was closed in November 2022. The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (“ZTlido”), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lid